Table 4 Multivariable model assessing the independent impact of clinically relevant covariates on progression-free survival after CAR T-cell therapy for relapsed/refractory multiple myeloma.

From: Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma

Characteristic

N

Event N

HR

95% CI

p-value

Performance Status

86

69

  

0.021

 ECOG 0

  

—

—

 

 ECOG 1–2

  

1.84

1.09, 3.12

 

High-risk Cytogenetics

86

69

  

0.18

 No

  

—

—

 

 Yes

  

1.44

0.84, 2.47

 

Prior BCMA-directed Therapy

86

69

  

0.18

 No

  

—

—

 

 Yes

  

1.78

0.78, 4.05

 

Bridging Therapy

86

69

  

0.25

 No

  

—

—

 

 Yes

  

1.45

0.76, 2.76

 

High Tumor Burden

86

69

  

0.062

 No (<50% BMPCs)

  

—

—

 

 Yes (≥50% BMPCs)

  

1.85

0.98, 3.52

 

CRS/ICANS management

86

69

  

0.30

CRS/ICANS (No Treatment)

  

—

—

 

No CRS/ICANS

  

1.56

0.75, 3.21

 

CRS/ICANS (CCS ± TCZ)

  

0.74

0.36, 1.51

 

CRS/ICANS (TCZ only)

  

1.11

0.50, 2.46

 
  1. BMPC bone marrow plasma cell, BCMA B-cell maturation antigen, CCS corticosteroid, CI confidence interval, CRS cytokine release syndrome, ECOG Eastern Cooperative Oncology Group, HR hazard ratio, ICANS immune effector cell-associated neurotoxicity syndrome, TCZ tocilizumab.
Back to article page